BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34402431)

  • 21. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4.
    Hosoda W; Chianchiano P; Griffin JF; Pittman ME; Brosens LA; Noë M; Yu J; Shindo K; Suenaga M; Rezaee N; Yonescu R; Ning Y; Albores-Saavedra J; Yoshizawa N; Harada K; Yoshizawa A; Hanada K; Yonehara S; Shimizu M; Uehara T; Samra JS; Gill AJ; Wolfgang CL; Goggins MG; Hruban RH; Wood LD
    J Pathol; 2017 May; 242(1):16-23. PubMed ID: 28188630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
    Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
    J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.
    Morse MA; Chawla SP; Wong TZ; Bruckner HW; Hall FL; Gordon EM
    Mol Clin Oncol; 2021 Sep; 15(3):186. PubMed ID: 34277005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by
    Hu S; Chen X; Xu X; Zheng C; Huang W; Zhou Y; Akuetteh PDP; Yang H; Shi K; Chen B; Zhang Q
    Front Oncol; 2020; 10():594224. PubMed ID: 33134183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
    Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
    [No Abstract]   [Full Text] [Related]  

  • 29. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pancreatic carcinogenesis. Clinical implications].
    Schneider G; Lersch C; Schmid RM
    Chirurg; 2003 Mar; 74(3):165-70. PubMed ID: 12647072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
    Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
    Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas.
    Lu L; Zeng J
    PLoS One; 2017; 12(7):e0181532. PubMed ID: 28742845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
    Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
    Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 36. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.
    Kim MJ; Kim MS; Kim SJ; An S; Park J; Park H; Lee JH; Song KB; Hwang DW; Chang S; Kim KP; Jeong SY; Kim SC; Hong SM
    Cancer Cell Int; 2017; 17():47. PubMed ID: 28435405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.
    Godfrey JD; Morton JP; Wilczynska A; Sansom OJ; Bushell MD
    Cell Death Dis; 2018 May; 9(6):644. PubMed ID: 29844410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset.
    Ho J; Li X; Zhang L; Liang Y; Hu W; Yau JCW; Chan H; Gin T; Chan MTV; Tse G; Wu WKK
    Semin Cancer Biol; 2019 Apr; 55():70-77. PubMed ID: 29705685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.